Menu Search
Equities

ImpediMed Ltd

IPDQF:PKC

ImpediMed Ltd

Actions
  • Price (USD)0.0344
  • Today's Change0.00 / 0.00%
  • Shares traded75.00k
  • 1 Year change-62.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 19:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.

  • Revenue in AUD (TTM)10.32m
  • Net income in AUD-19.79m
  • Incorporated1999
  • Employees83.00
  • Location
    ImpediMed LtdPinkenba, U 1 50 Parker CtBRISBANE 4008AustraliaAUS
  • Phone+61 73860-3700
  • Fax+61 73260-1225
  • Websitehttps://www.impedimed.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.